Project Grant R21AI182884
Award Date
11/14/24
Completion Date
10/31/26
Dollars Obligated
$212K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $657,506 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The grant supports research to develop a novel subunit vaccine against Bordetella pertussis, the causative agent of pertussis (whooping cough), which aims to elicit mucosal immunity and prevent nasal colonization to reduce disease transmission. The research focuses on evaluating a subunit...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $780,834 to Michigan State University to develop a next-generation carbohydrate-based multi-component vaccine against the bacterial pathogen Bordetella pertussis, which causes whooping cough. The 5-year project aims to: 1) synthesize pertussis-associated glycan antigens, 2) conjugate the synthetic glycans to the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $910,426 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Rector & Visitors of the University of Virginia (UVA). The grant supports research to gain mechanistic insights into how Fc receptors mediate the transfer of immunoglobulin G (IgG) from mother to fetus across the placenta. This research aims to optimize maternal vaccine strategies for protecting infants...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $793,102 to Wake Forest University Health Sciences (WFUHS) to investigate the interplay of maternal antibody and newborn vaccine responses to influenza virus. The goal is to effectively vaccinate young infants when maternal antibody levels are high, so that as maternal antibody wanes, a protective...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $192,260 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Virginia (UVA). The 5-year grant, active from March 1, 2025 to February 28, 2030, supports research to characterize the systemic and mucosal immune response to adenovirus 40/41 infection in Bangladeshi children. The grant has two key objectives: 1) Describe the antibody repertoire to adenovirus 40/41 in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,336,490 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Sloan-Kettering Institute for Cancer Research in New York, NY. The 5-year grant, awarded on August 6, 2024, supports research to understand B cell and antibody responses to placental versus foreign antigens, with the goal of illuminating how dysregulated responses contribute to pregnancy complications and informing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $534,418 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Georgia Research Foundation, Inc. The five-year grant, awarded on August 1, 2025, will investigate how components of human breastmilk can suppress the survival of the pathogenic bacterium Campylobacter jejuni, a major cause of diarrheal disease worldwide. The project aims to identify the specific...
This $797,735 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the cellular and molecular mechanisms governing heightened immune responses in neonates. The research project will utilize a novel mouse model to investigate how the innate immune system detects and mediates sterile inflammation during early life development, with the goal of developing targeted...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $207,262 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The grant supports the development of an mRNA vaccine against Bourbon virus, an emerging tick-borne RNA virus that can infect and cause disease in humans. The primary objectives are to evaluate the vaccine's efficacy in a mouse model and determine its mechanism of action. A...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $402,731 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Washington. The objective of this R38 grant is to increase the number of next generation physician-scientists who can apply knowledge of microbiology, immunology, and research techniques to improve reproductive, maternal, and child health. The grant will support 4 physician-scientists in...